Enfuvirtide: from basic investigations to current clinical use

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

(2009) Jean-Paul Viard et al.   AIDS

Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial

(2009) Nathalie De Castro et al.   CLINICAL INFECTIOUS DISEASES

Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals

(2009) Luigia Elzi et al.   HIV CLINICAL TRIALS

Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure

(2009) Pablo Tebas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study

(2009) William Towner et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?

(2009) I. Kousignian et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide

(2009) N. Ray et al.   JOURNAL OF VIROLOGY

Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation

(2009) Elina Teicher et al.   LIVER TRANSPLANTATION

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

(2008) Marianne Harris et al.   AIDS

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study

(2008) Bonaventura Clotet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY